OPEN END TURBO CALL WARRANT - GILEAD SCIENCES | Market Closed - Boerse Frankfurt Warrants 18:27:32 27/06/2024 BST | ||
| 3.16 EUR | -2.17% |
|
| Current month | +21.07% | ||
| 1 month | +13.26% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 3.16 | -2.17% |
| 26/06/24 | 3.23 | -1.52% |
| 25/06/24 | 3.28 | -2.96% |
| 24/06/24 | 3.38 | +2.74% |
| 21/06/24 | 3.29 | +2.49% |
Real-time Boerse Frankfurt Warrants
Last update June 27, 2024 at 06:27 pm
More quotesStatic data
| Product type | Knock-Out sin Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | UBS |
| WKN | UH4955 |
| ISIN | DE000UH49551 |
| Date issued | 03/12/2021 |
| Strike | 35.37 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.06 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.26 € |
|---|---|
| Lowest since issue | 2.17 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
68.83
USD
Average target price
82.97
USD
Spread / Average Target
+20.54%
- Stock Market
- Certificates
- Certificat
